中文摘要：

在当前的药发现有高现出症状之前的潜的摩擦率。在在整个屏蔽的候选人药的高度的有效评价途径仍然需要大改进。我们建议二个假设。首先，两个都，药行动过程和生物过程能被变换成介绍的基因或基因产品的一个普通空格。第二，生物过程上的药行动的力量能在生物网络的上下文被认识到。基于上述假设，我们建立一个算法为药行动(NADA ) 到的称为的基于网络的评价在某些生物过程上估计候选人药的行动力量。然后， NADA 被用来在 endothelial 房间移植上从繁体中文药优先考虑六混合物的效果，简单进程由基因本体论定义在为给定的病理学的进程特定的生物网络， angiogenesis。计算结果被人的脐的静脉 Endothelial 房间的迁居的实验随后在 vitro 测试。为六混合物的试验性的等级通常同意 NADA 的预言的产量。NADA 也以试验性的订单超过 DAVID 和 meet/min 方法，建议拓扑的特征可以有的网络在抓住在药行动和生物过程之间的机械学的关系的一个关键角色。希望，网络生物学的进步来临因为译解的复杂疾病将进一步帮助现出症状之前的潜的屏蔽并且加速处理形式的开发。

英文摘要：

There are high preclinical attrition rates in current drug discovery. The efficient assessment approach in the high throughout candidate drugs screening still needs great improvement. We propose two hypotheses. First, both drug action process and biological process can be converted to a common space of gene or gene product profiling. Second, the strength of drug action on biological process can be realized in the context of biological network. Based on the above hypotheses, we establish an algorithm termed Network-based Assessment for Drug Action （NADA） to assess the action strength of candidate drugs on certain biological processes. Then NADA is used to prioritize the effects of six compounds from traditional Chinese medicine on endothelial cell migration, a simple process defined by Gene Ontology, in the biological network specific for a given pathological process, angiogenesis The computational results are subsequently tested by the experiment on the migration of Human Umbilical Vein Endothelial Cells in vitro. The experimental ranks for six compounds generally agree with the predicted output of NADA, NADA also outperforms the DAVID and meet/rain methods in terms of the experimental orders, suggesting that the network topological features may have a key role in catching the mechanistic relationship between drug action and biological process. Hopefully, the progress of network biology approaches for deciphering complex diseases will further expedite the preclinical screening and accelerate the development of treatment modalities.